Most importantly, GLP-1 analogs do not carry the risk of neuroglycopenia in patients with Alzheimer’s disease, which could potentially lead to cognitive decline in this group of patients [193]. The gene discussed is GLP1R; the disease is early-onset autosomal dominant Alzheimer disease.